Latest news with #Pulmonary
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
On May 28, Oren Livnat, an analyst from H.C. Wainwright initiated coverage of Trevi Therapeutics, Inc. (NASDAQ:TRVI) with a Buy rating and a $21 price target. The update comes after the company released additional analysis from the Phase 2a RIVER trial of Haduvio in patients with Refractory Chronic Cough. Closeup of a biopharmaceutical worker holding a beaker of white liquid in a laboratory. The company released additional analysis from phase 2a RIVER trial suggesting a more de-risked path to approval as compared to the current market expectations, said the analyst. He believes that the company can achieve over $1 billion in revenue from the drug's treatment of refractory chronic cough alone. Moreover, the Idiopathic Pulmonary Fibrosis chronic cough could be another significant revenue stream for Trevi Therapeutics, Inc. (NASDAQ:TRVI). The current market capitalization of the company is around $627 million which is undervalued considering the strong results from the RIVER trial, said the analyst. Livna expects Haduvio to become a best-in-class for both Idiopathic Pulmonary Fibrosis and refractory chronic cough. Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, which is an investigational therapy aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. While we acknowledge the potential of TRVI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRVI and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
On May 28, Oren Livnat, an analyst from H.C. Wainwright initiated coverage of Trevi Therapeutics, Inc. (NASDAQ:TRVI) with a Buy rating and a $21 price target. The update comes after the company released additional analysis from the Phase 2a RIVER trial of Haduvio in patients with Refractory Chronic Cough. Closeup of a biopharmaceutical worker holding a beaker of white liquid in a laboratory. The company released additional analysis from phase 2a RIVER trial suggesting a more de-risked path to approval as compared to the current market expectations, said the analyst. He believes that the company can achieve over $1 billion in revenue from the drug's treatment of refractory chronic cough alone. Moreover, the Idiopathic Pulmonary Fibrosis chronic cough could be another significant revenue stream for Trevi Therapeutics, Inc. (NASDAQ:TRVI). The current market capitalization of the company is around $627 million which is undervalued considering the strong results from the RIVER trial, said the analyst. Livna expects Haduvio to become a best-in-class for both Idiopathic Pulmonary Fibrosis and refractory chronic cough. Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, which is an investigational therapy aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. While we acknowledge the potential of TRVI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRVI and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None.
Yahoo
27-05-2025
- Business
- Yahoo
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced an upcoming presentation at the European Congress of Rheumatology (EULAR) 2025, being held June 11-14, 2025, in Barcelona, Spain. Avalyn's poster presentation at EULAR 2025 will include the Phase 2b study design of AP01 (inhaled pirfenidone) in various forms of progressive pulmonary fibrosis (PPF), including autoimmune ILDs. EULAR 2025 Poster Presentation: Title: Inhaled Pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study DesignAuthors: Colin Reisner, Sebastien Tilleux, Allison Trucillo, Deepthi Nair, Felix Woodhead, Howard M. Lazarus, Craig Conoscenti, Martin Kolb About Avalyn PharmaAvalyn is reimagining the future of pulmonary fibrosis treatment with a pipeline of new inhaled formulations of approved medicines. Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, reduced exercise capacity, and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn's inhaled approach tackles the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs, thereby improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Avalyn's AP01 is an optimized inhaled formulation of pirfenidone, currently being studied in the ongoing MIST Phase 2b study in progressive pulmonary fibrosis (PPF). AP01 has been assessed in over 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety compared to historical data with existing therapies. The company completed two Phase 1 studies for AP02, inhaled nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). For more information, please visit and follow us on LinkedIn. Investor Contact:Alex Straus, THRUST alex@ Media Contact:media@
Globe and Mail
17-02-2025
- Health
- Globe and Mail
COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market
The Chronic Pulmonary Hypertension market growth is driven by factors like increase in the prevalence of Chronic Pulmonary Hypertension, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Chronic Pulmonary Hypertension market report also offers comprehensive insights into the Chronic Pulmonary Hypertension market size, share, Chronic Pulmonary Hypertension epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Pulmonary Hypertension market size growth forward. Some of the key highlights from the Chronic Pulmonary Hypertension Market Insights Report: Several key pharmaceutical companies, including COMPASS Pathways, Homeostasis Therapeutics, LLC, and others, are developing novel products to improve the Chronic Pulmonary Hypertension treatment outlook. In January 2025, AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for treating pulmonary arterial hypertension (PAH), a rare and life-threatening condition characterized by high blood pressure in the lung arteries, which can lead to right-sided heart failure. In December 2024, Nicox announced that its Denali Phase III trial, assessing the efficacy and safety of NCX470 for patients with open-angle glaucoma or ocular hypertension, has completed enrollment in China, and screening has concluded. In November 2024, MediPrint Ophthalmics revealed the results of its Phase IIb clinical trial for LL-BMT1. The trial utilized a new 3D-printed, drug-eluting contact lens for continuous delivery of bimatoprost and hyaluronic acid, successfully meeting all the Phase IIb endpoints. The prevalence of chronic pulmonary hypertension is expected to rise due to factors such as aging populations, increasing obesity rates, better survival rates among premature infants, environmental influences, genetic factors, improved diagnostics, and a rise in comorbidities. In 2023, the US represented the largest share of diagnosed chronic pulmonary hypertension patients in the 7MM, with 42%, followed by Japan, which accounted for around 16% of cases. Among European countries, the UK had the highest number of cases, representing approximately 11% of the total 7MM cases. In 2023, the chronic pulmonary hypertension market was the largest in the US, with a market size of about USD 15,700 million, a figure expected to grow by 2034. Despite the high prevalence, with around 42,476 thousand cases in the 7MM in 2023, the market for chronic pulmonary hypertension treatment remains limited, with few therapies specifically targeting the condition. However, emerging therapies could significantly impact the market, potentially driving substantial growth. As per DelveInsight analysis, the Chronic Pulmonary Hypertension market is anticipated to witness growth at a considerable CAGR Strategise your business goals by understanding market dynamics @ Chronic Pulmonary Hypertension Market Landscape Chronic Pulmonary Hypertension Overview Chronic pulmonary hypertension is a condition characterized by high blood pressure in the lungs, which places strain on the heart and can lead to severe symptoms like shortness of breath and fatigue. It is classified into five groups: Group 1 includes pulmonary arterial hypertension (PAH), Group 2 is pulmonary hypertension caused by left heart disease, Group 3 is pulmonary hypertension linked to lung diseases and/or hypoxia, Group 4 refers to chronic thromboembolic pulmonary hypertension (CTEPH), and Group 5 encompasses pulmonary hypertension with unknown or multifactorial causes. Early detection and proper treatment are essential to improve outcomes and quality of life. Diagnosing chronic pulmonary hypertension involves a combination of clinical assessment, imaging, and specialized tests. Challenges can arise due to the nonspecific nature of the symptoms and the need to differentiate pulmonary hypertension from other cardiovascular and respiratory conditions. Diagnostic methods include echocardiography to evaluate heart function and estimate pulmonary artery pressure, followed by confirmatory tests like right heart catheterization, which directly measures pulmonary artery pressures. Accurate interpretation of results can be challenging, especially in cases where other heart or lung conditions are present, requiring a thorough differential diagnosis. Do you know the treatment paradigms for different countries? Download our Chronic Pulmonary Hypertension Market Sample Report Chronic Pulmonary Hypertension Epidemiology Insights The number of chronic pulmonary hypertension cases in the US is projected to grow at a significant compound annual growth rate (CAGR) by 2034, starting from approximately 17,910 thousand cases in 2023. In Europe, Germany had the highest prevalence of chronic pulmonary hypertension, accounting for 26% of cases, followed by the UK in 2023. Conversely, Spain had the lowest prevalence, with around 15% of the total diagnosed cases of chronic pulmonary hypertension in the same year. Chronic Pulmonary Hypertension Epidemiology Segmentation DelveInsight's Chronic Pulmonary Hypertension market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Pulmonary Hypertension historical patient pools and forecasted Chronic Pulmonary Hypertension patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Pulmonary Hypertension Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into: Chronic Pulmonary Hypertension Prevalence Age-Specific Chronic Pulmonary Hypertension Prevalence Gender-Specific Chronic Pulmonary Hypertension Prevalence Diagnosed and Treatable Cases of Chronic Pulmonary Hypertension Visit for more @ Chronic Pulmonary Hypertension Epidemiological Insights Chronic Pulmonary Hypertension Market Outlook Phosphodiesterase-5 (PDE-5) inhibitors like Sildenafil and Tadalafil help reduce vascular smooth muscle cell proliferation and promote vasodilation. Endothelin receptor antagonists, including Ambrisentan, Bosentan, and Macitentan, counteract vasoconstriction and smooth muscle cell growth in the pulmonary arteries. Commonly used calcium channel blockers, such as Nifedipine, diltiazem, and amlodipine, are recommended for treating Pulmonary Arterial Hypertension (PAH). Prostacyclins like epoprostenol, treprostinil, and iloprost improve functional capacity and survival in PAH patients. Additionally, IP prostacyclin receptor agonists, which activate the prostacyclin pathway, are also used for chronic pulmonary hypertension (PH). Endothelin receptor antagonists reduce endothelin-1 levels, which cause constriction and changes in the pulmonary blood vessels in PAH patients. PDE-5 inhibitors and soluble guanylate cyclase (sGC) stimulators help lower enzyme levels that produce nitric oxide (NO), a substance that relaxes pulmonary blood vessels. By increasing cyclic GMP levels, these drugs promote vasodilation. PDE-5 inhibitors prevent the breakdown of cyclic GMP, while sGC stimulators enhance cyclic GMP production when NO binds to the sGC enzyme, making them effective treatments for PAH. Chronic Pulmonary Hypertension Marketed Drugs ADEMPAS (riociguat): Bayer Chronic Pulmonary Hypertension Emerging Drugs CS1: Cereno Scientific AB Chronic Pulmonary Hypertension Key Companies COMPASS Pathways, Homeostasis Therapeutics, LLC, and others For more information, visit Chronic Pulmonary Hypertension Market Analysis, Patient Pool, and Emerging Therapies Scope of the Chronic Pulmonary Hypertension Market Report: 11 Years Forecast 7MM Coverage Descriptive overview of Chronic Pulmonary Hypertension, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Chronic Pulmonary Hypertension epidemiology in the 7MM Chronic Pulmonary Hypertension marketed and emerging therapies Chronic Pulmonary Hypertension companies Chronic Pulmonary Hypertension market drivers and barriers Table of Contents: 1 Chronic Pulmonary Hypertension Market Key Comprehensive Insights 2 Chronic Pulmonary Hypertension Market Report Introduction 3 Competitive Intelligence Analysis for Chronic Pulmonary Hypertension 4 Chronic Pulmonary Hypertension Market Analysis Overview at a Glance 5 Executive Summary of Chronic Pulmonary Hypertension 6 Chronic Pulmonary Hypertension Epidemiology and Market Methodology 7 Chronic Pulmonary Hypertension Epidemiology and Patient Population 8 Chronic Pulmonary Hypertension Patient Journey 9 Chronic Pulmonary Hypertension Treatment Algorithm, Chronic Pulmonary Hypertension Current Treatment, and Medical Practices 10 Key Endpoints in Chronic Pulmonary Hypertension Clinical Trials 11 Chronic Pulmonary Hypertension Marketed Therapies 12 Chronic Pulmonary Hypertension Emerging Therapies 13 Chronic Pulmonary Hypertension: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Chronic Pulmonary Hypertension 16 Chronic Pulmonary Hypertension Market Key Opinion Leaders Reviews 18 Chronic Pulmonary Hypertension Market Drivers 19 Chronic Pulmonary Hypertension Market Barriers 20 SWOT Analysis 21 Disclaimer 22 DelveInsight Capabilities 23 About DelveInsight Related Reports: Chronic Pulmonary Hypertension Epidemiology 2034 DelveInsight's "Chronic Pulmonary Hypertension - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Pulmonary Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Chronic Pulmonary Hypertension Pipeline 2024 "Chronic Pulmonary Hypertension Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pulmonary Hypertension market. A detailed picture of the Chronic Pulmonary Hypertension pipeline landscape is provided, which includes the disease overview and Chronic Pulmonary Hypertension treatment guidelines. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Yahoo
08-02-2025
- Health
- Yahoo
Doctors urge people to get vaccinated after surge in TN flu cases
NASHVILLE, Tenn. (WKRN) — Flu cases have surged and forced some Middle Tennessee school districts to cancel classes. This week, several Middle Tennessee school districts closed their doors to undergo deep cleaning and allow students and faulty to heal before returning on Monday. 'We call it kind of a double peak,' Dr. Todd Rice, professor of medicine with the Vanderbilt University Medical Center Division of Allergy, Pulmonary, & Critical Care, said. 'We are starting to see a little bounce from the first peak and it came down. Now, it's going back up again.' Kentucky reports first pediatric flu death of 2024-2025 respiratory illness season A map published by the Centers for Disease Control & Prevention (CDC) showed Tennessee was one of nearly a dozen states with a 'very high' level of flu-like illness for the week ending on Feb. 1. Inside hospitals across the state, doctors have worked with patients who suffer with severe symptoms. 'You get high fevers, a bad cough and muscle aches that are just debilitating,' Rice said. 'They make it so you can barely get out of bed.' As a result, schools across Middle Tennessee called off classes — some even closed their doors for multiple days as students and teachers were overwhelmed with illness. The time off has helped them recover from illness and allow schools to sanitize. 'When I saw schools saying, 'We're not going to have school today because so many kids are out and teachers are out and that sort of stuff,' I said, 'Oh yea, this second peak is probably being driven by schools and kids in school.'' Doctors have also reported an increase in COVID-19, RSV, and Norovirus cases, which have been referred to as the 'winter quad-demic.' 'I anticipate in the next week or so that we'll see rising rates again in the hospital as there is this little bit of a delay between the community cases and the hospitalized cases,' Rice said. Although doctors say the best time to get the flu vaccine is in the early fall, they've encouraged people to get a shot now if they haven't already, saying it's not too late to be vaccinated. What is influenza A, the type of flu making people so sick right now? 'People told me during that first peak that we were kind of seeing around the holidays, 'Well. it's too late, we are already seeing influenza,'' Rice said. 'Had you gotten vaccinated at that point, you would have been protected at this point and hopefully have less severe disease if you got the flu.' Rice said no one is immune from the virus, but there are some people more at risk to get the flu. Members of the older population and those who are under 6 are the most at risk for the virus. As of publication, most school districts in Middle Tennessee plan to open school on time Monday morning. You can follow this link to keep track of all school closings. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
